InflaRx Announces Peer-Reviewed Publication Of First-In-Human Phase 1 Clinical Data For Izicopan, Orally Administered, Next-Gen Small Molecule Inhibitor Of C5a Receptor
Izicopan achieved rapid and sustained inhibition of C5a/C5aR1 signalingPharmacokinetic results demonstrated dose-dependent exposure, with izicopan well tolerated across all single and multiple doses evaluatedFindings
InflaRx published lab results showing their new medicine works safely. This is an early step that hints the company might have a real drug.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.